MedTrace Logo

Pazopanib Vs. Pazopanib Plus Gemcitabine

NCT02203760 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-11-15

No results posted yet for this study

Summary

This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.

Conditions

  • Leiomyosarcoma or Carcinosarcoma

Interventions

DRUG

Pazopanib plus Gemcitabine

Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or

DRUG

Pazopanib

Pazopanib 800 mg orally once daily

Sponsors & Collaborators

  • Novartis Pharmaceuticals

    collaborator INDUSTRY

  • medac GmbH

    collaborator INDUSTRY

  • North Eastern German Society of Gynaecological Oncology

    lead OTHER

Principal Investigators

  • Alexander Mustea, Prof. Dr. med. · University Hospital, Bonn

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-16
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02203760 on ClinicalTrials.gov